Skip to main content
SpringerLink
Log in

Statins: Risk-Benefits and Role in Treating Dyslipidemias

  • Chapter
  • First Online:
Dyslipidemias

Part of the book series: Contemporary Endocrinology ((COE))

  • 2280 Accesses

Abstract

Statins are the mainstay of therapy for the management of dyslipidemia, and particularly elevations in low-density lipoprotein cholesterol (LDL-C). Currently available statins include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. The advent of statin therapy has contributed to a substantial decrease in cardiovascular mortality over the past several decades. Results from multiple clinical trials have shown conclusively that lowering LDL-C levels leads to clinical event reduction in primary and secondary prevention, for both men and women, and across various other patient subgroups. Extensive clinical experience indicates that statin therapy may be initiated and maintained over the long term with a high degree of safety, and adverse effects associated with statin use are outweighed by their proven benefits in clinical event reduction.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285:2486–97.

    Article  Google Scholar 

  2. Grundy SM, Cleeman JI, Merz CNB, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.

    Article  PubMed  Google Scholar 

  3. Product information. Lipitor (atorvastatin). New York: Pfizer; (February 2012.

    Google Scholar 

  4. Product information. Lescol, Lescol XL (fluvastatin). East Hanover: Novartis Pharmaceuticals Corporation; (February 2012).

    Google Scholar 

  5. Product information. Mevacor (lovastatin). Whitehouse Station: Merck; (February 2012).

    Google Scholar 

  6. Product information. Livalo (pitavastatin). Montgomery: Kowa; (June 2012).

    Google Scholar 

  7. Product information. Pravachol (pravastatin). Princeton: Bristol-Myers Squibb; (February 2012).

    Google Scholar 

  8. Product information. Crestor (rosuvastatin). Wilmington: AstraZeneca; (February 2012).

    Google Scholar 

  9. Product information. Zocor (simvastatin). Whitehouse Station: Merck; (June 2012).

    Google Scholar 

  10. Centers for Disease Control (Internet). Total and high-density lipoprotein cholesterol in adults: National Health and Nutrition Examination Survey, 2009–2010. 2012 Apr ([cited 2012 Sept 5];92). http://www.cdc.gov/nchs/data/databriefs/db92.htm.

  11. National Heart, Lung, and Blood Institute (Internet). Morbidity & mortality: Chart Book on Cardiovascular, Lung, and Blood Diseases. [cited 2012 Sept 5] 2012. http://www.nhlbi.nih.gov/resources/docs/cht-book.htm.

  12. Steinberg D. The cholesterol wars: the skeptics vs. the preponderance of the evidence. San Diego: Elsevier; 2007.

    Google Scholar 

  13. Endo A. The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl. 2004 ;5(3):67–80.

    Article  CAS  PubMed  Google Scholar 

  14. Gotto AM, Pownall HJ. Manual of lipid disorders: reducing the risk for coronary heart disease. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2003.

    Google Scholar 

  15. McKenney JM, Ganz P, Wiggins BS, Saseen JS. Statins. In: Ballantyne CM, editor. Clinical lipidology: a companion to Braunwald’s Heart Disease. Philadelphia: Elsevier; 2009. p. 253–80.

    Chapter  Google Scholar 

  16. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther. 2006;80(6):565–81.

    Article  CAS  PubMed  Google Scholar 

  17. Prueksaritanont T, Tang C, Qui Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metabo Disp. 2002;30(11):1280–87.

    Article  CAS  Google Scholar 

  18. Sadowitz B, Maier KG, Gahtan V. Basic science review: statin therapy–Part I: The pleiotropic effects of statins in cardiovascular disease. Vasc Endovascular Surg. 2010; 44(4):241–51.

    Article  PubMed  Google Scholar 

  19. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    Article  CAS  PubMed  Google Scholar 

  20. Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012; 125(6):757–66.

    Article  CAS  PubMed  Google Scholar 

  21. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005;46:1855–62.

    Article  CAS  PubMed  Google Scholar 

  22. US Food and Drug Administration (Internet). FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. June 8, 2011. http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed 26 Sept 2012.

  23. Mangravite LM, Krauss RM. Pharmacogenomics of statin response. Curr Opin Lipidol. 2007;18(4):409–14.

    CAS  PubMed  Google Scholar 

  24. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2):152–60.

    Article  CAS  PubMed  Google Scholar 

  25. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69–76.

    Article  CAS  PubMed  Google Scholar 

  26. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet. 2010; 376:1658–69.

    Article  PubMed  Google Scholar 

  27. Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.

    Article  CAS  PubMed  Google Scholar 

  28. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.

    Article  Google Scholar 

  29. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–9.

    Article  CAS  PubMed  Google Scholar 

  30. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–22.

    Article  CAS  PubMed  Google Scholar 

  31. Heart Protection Study Collaborative Group. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomized controlled trial. Lancet. 2011; 378(9808):2013–20.

    Article  PubMed Central  Google Scholar 

  32. Strandberg TE, Pyörälä K, Cook TJ, Wilhelmsen L Faegerman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the scandinavian simvastatin survival study (4S). Lancet. 2004;364(9436):771–7.

    Article  CAS  PubMed  Google Scholar 

  33. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease). Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet. 2002;359(9315):1379–87.

    Article  Google Scholar 

  34. Armitage J. The safety of statins in clinical practice. Lancet. 2007;370(9601):1781–90.

    Article  CAS  PubMed  Google Scholar 

  35. US Food and Drug Administration (Internet). FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs [published 2012 Feb 28; cited 2012 Sept 4]. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.

  36. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C–94C.

    Article  CAS  PubMed  Google Scholar 

  37. Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy. 2008;28(4):522–9.

    Article  CAS  PubMed  Google Scholar 

  38. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006;97(suppl):52C–60C.

    Article  CAS  PubMed  Google Scholar 

  39. Jacobson TA. Toward “pain-free” statin prescribing: clinical algorithm for diagnosis and management of myalgia. Mayo Clin Proc. 2008;83(6):687–700.

    Article  PubMed  Google Scholar 

  40. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med. 2008;359(8):789–99.

    Article  CAS  PubMed  Google Scholar 

  41. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009;54(17):1609–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Harper CR, Jacobson TA. Evidence-based management of statin myopathy. Curr Atheroscler Rep. 2010;12:322–30.

    Article  CAS  PubMed  Google Scholar 

  43. Sattar N, Preiss D, Murray HM, Welsh P, Buckley DM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375(9716):735–42.

    Article  CAS  PubMed  Google Scholar 

  44. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA. 2011; 305:2556–64.

    Article  CAS  PubMed  Google Scholar 

  46. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012; 172(2):144–52.

    Article  PubMed  Google Scholar 

  47. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008; 371:117–25.

    Article  Google Scholar 

  48. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71–105.

    Article  CAS  PubMed  Google Scholar 

  49. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1563–74.

    Article  PubMed  Google Scholar 

  50. Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol. 2007;99(6A):22C–31C.

    Article  CAS  PubMed  Google Scholar 

  51. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.

    Article  CAS  PubMed  Google Scholar 

  52. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59:572–82.

    Article  CAS  PubMed  Google Scholar 

  53. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.

    Article  CAS  PubMed  Google Scholar 

  54. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.

    Article  CAS  PubMed  Google Scholar 

  55. Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update. Circulation. 2011;124:2458–73.

    Article  PubMed  Google Scholar 

  56. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:pii: S0735-1097(13)06028–2. 10.1016/j.jacc.2013. 11.002 (epub ahead of print).

    Google Scholar 

  57. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2011;19(1):CD004816.

    Google Scholar 

  59. Lazar LD, Pletcher MJ, Coxson PG, Bibbins-Domingo K, Goldman L. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011;124:146–53.

    Article  CAS  PubMed  Google Scholar 

  60. Cholesterol Treatment Trialists’ (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012; 380(9841): 581–90.

    Article  Google Scholar 

  61. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301–7.

    Article  CAS  PubMed  Google Scholar 

  62. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349–57.

    Article  Google Scholar 

  63. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.

    Google Scholar 

  64. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;287(4):3215–22.

    Article  CAS  PubMed  Google Scholar 

  65. Herd JA, Ballantyne CM, Farmer JA, Fergus JJ 3rd, Jones PH, West MS, et al. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997;80:278–86.

    Article  CAS  PubMed  Google Scholar 

  66. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.

    Article  CAS  PubMed  Google Scholar 

  67. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364(9435):685–96.

    Article  CAS  PubMed  Google Scholar 

  68. Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial—lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151–57.

    Article  CAS  PubMed  Google Scholar 

  69. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29(6):1220–6.

    Article  CAS  PubMed  Google Scholar 

  70. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549–59.

    Article  CAS  PubMed  Google Scholar 

  71. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071–1080.

    Article  CAS  PubMed  Google Scholar 

  72. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295:1556–1565.

    Article  CAS  PubMed  Google Scholar 

  73. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297:1344–1353.

    Article  CAS  PubMed  Google Scholar 

  74. Budinski D, Arneson V, Hounslow N, Gratsiansky N. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009; 4(3):291–302.

    Article  CAS  Google Scholar 

  75. Ose L, Budinski D, Hounslow N, Arneson V. Comparison of pitavastatin with simvastatin in primary hypercholesterolemia or combined dyslipidemia. Curr Med Res Opin. 2009;25(10): 2755–64.

    CAS  PubMed  Google Scholar 

  76. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome. J Am Coll Cardiol. 2009; 54(4):293–302.

    Article  PubMed  Google Scholar 

  77. Yokote K, Shimano H, Urashima M, Teramoto T. Efficacy and safety of pitavastatin in Japanese patients with hypercholesterolemia: LIVES study and subanalysis. Expert Rev Cardiovasc Ther. 2011;9(5):555–62.

    Article  CAS  PubMed  Google Scholar 

  78. National Heart, Lung, and Blood Institute. Expert Panel on Integrated Guidelines for cardiovascular Health and risk reduction in children and adolescents. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics. 2011;128(Suppl 5): S213–56.

    Google Scholar 

  79. Goldberg AC, Hopkins PN, Toth PP, Ballantyne CM, Rader DJ, Robinson JG, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5:133–40.

    Article  PubMed  Google Scholar 

  80. Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. Ann Pharmacother. 2012;46(10):1419–24.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Weill Cornell Medical College, 1305 York Avenue, Y-805, 10021, New York, NY, USA

    Antonio M. Gotto MD, DPhil & Jennifer E. Moon PhD

Authors
  1. Antonio M. Gotto MD, DPhil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer E. Moon PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio M. Gotto MD, DPhil .

Editor information

Editors and Affiliations

  1. Professor of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA

    Abhimanyu Garg

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Humana Press

About this chapter

Cite this chapter

Gotto, A., Moon, J. (2015). Statins: Risk-Benefits and Role in Treating Dyslipidemias. In: Garg, A. (eds) Dyslipidemias. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-424-1_24

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-424-1_24

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-423-4

  • Online ISBN: 978-1-60761-424-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation